NIKKEI 225
38,719.35 -227.58 (-0.58%) HANG SENG
19,242.67 +22.05 (+0.11%) CRUDE OIL
79.06 -0.20 (-0.25%) GOLD FUTURES
2,420.50 -5.40 (-0.22%) DOW
39,872.99 +66.22 (+0.17%) Bitcoin GBP
55,030.09 -1,109.03 (-1.98%)
Oncolytics Biotech Inc (ONYN.BE)
| Previous close | 1.0300 |
| Open | 1.0200 |
| Bid | 0.9400 x N/A |
| Ask | 1.0900 x N/A |
| Day's range | 1.0100 - 1.0200 |
| 52-week range | 0.8200 - 3.0000 |
| Volume | |
| Avg. volume | 88 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 12 Aug 2024 - 16 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireOncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the voting results from its Annual General Meeting (AGM) of Shareholders held on Wednesday, May 15, 2024. A total of 41.34% of the issued and outstanding common shares of the Corporation were represented either in person or by proxy at the meeting.
PR NewswireOncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it has entered into a preliminary collaboration with the Global Coalition for Adaptive Research (GCAR). The purpose of the preliminary collaboration is to commence planning activities for the evaluation of pelareorep in the treatment of first-line metastatic pancreatic ductal adenocarcinoma (PDAC) as part of GCAR's anticipated master protocol for m
Insider MonkeyOncolytics Biotech Inc. (NASDAQ:ONCY) Q1 2024 Earnings Call Transcript
Oncolytics Biotech Inc. (NASDAQ:ONCY) Q1 2024 Earnings Call Transcript May 9, 2024 Oncolytics Biotech Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon and welcome to Oncolytics Biotech’s First Quarter 2024 Conference Call. [Operator Instructions]. Please be advised […]
